Nimbus Therapeutics

98 articles about Nimbus Therapeutics

• Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor

  4/9/2021

  Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the presentation of data from the company’s HPK1 inhibitor program in a poster at the AACR Annual Meeting held virtually April 10-15, 2021.

• Nimbus Therapeutics to Present Updated Preclinical Data From HPK1 Inhibitor Program in Scientific Seminar

  11/5/2020

  Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, will host its second in a series of virtual seminars highlighting the latest data from its HPK1 program. The seminar, titled “Novel, Potent, Selective HPK1 Inhibitors Enhance Immune

• Nimbus Therapeutics to Present New Data on Novel HPK1 Inhibitors at Upcoming Scientific Conferences

  10/22/2020

  Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the presentation of new data on the company’s novel hematopoietic progenitor kinase 1 (HPK1) inhibitors at upcoming scientific conferences. At the 32 nd EORTC-NCI-AACR Symposium, from October 24-25, 2020, Nimbus will present new in vivo data, including target eng

• Nimbus Therapeutics Appoints Erin Cowhig as Chief People Officer

  10/19/2020

  Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the appointment of Erin Cowhig as Chief People Officer. In this newly created role, Ms. Cowhig will oversee all aspects of Nimbus’ human resources, talent acquisition and management, and diversity and inclusion efforts. “Our people are the reason for Nimbus’ many ye

• Nimbus Therapeutics Announces $60 Million Private Financing From New Investors to Advance Expanded Pipeline

  10/14/2020

  Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the close of a $60 million private financing round from life science investors RA Capital Management and BVF Partners L.P.

• Nimbus Therapeutics Appoints Abbas Kazimi as Chief Business Officer

  9/28/2020

  Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the promotion of Abbas Kazimi to Chief Business Officer. Mr. Kazimi, who previously served as Vice President of Business Development, has more than 15 years of experience directing strategic transactions within the life sciences industry. “Throughout his tenure wit

• Nimbus Therapeutics Presents Data on Novel HPK1 Inhibitor, Demonstrating Robust Inhibition of Tumor Growth In Vivo

  6/22/2020

  Nimbus Therapeutics Presents Data on Novel HPK1 Inhibitor, Demonstrating Robust Inhibition of Tumor Growth In Vivo

• Nimbus Therapeutics to Host Scientific Seminar on Promising Preclinical Data from HPK1 Program

  6/18/2020

  Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, will host a webcast seminar to discuss the latest data from its HPK1 program on Thursday, June 25, from 11 a.m. to 12 p.m. ET. The seminar will feature presentations by Nimbus’ scientific leadership that give a brief overview of the company’s discovery pipeline and a deeper dive on

• Nimbus Therapeutics Announces Expansion of Its Drug Discovery Pipeline Across Oncology, Immunology and Metabolism

  6/8/2020

  Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the expansion of the company’s pipeline of small molecule candidates across a range of highly prevalent human diseases. These preclinical programs — AMPKβ2 (

• Nimbus Therapeutics Announces Promotion of Alan Collis, Ph.D., to Senior Vice President, Preclinical Development

  5/29/2020

  Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the promotion of Alan Collis, Ph.D., to Senior Vice President, Preclinical Development.

• Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1 Inhibitor With Robust In Vivo Activity

  5/15/2020

  Data to be presented at 2020 AACR Annual Meeting show HPK1 inhibition produced robust anti-tumor response in mouse model

• Nimbus Therapeutics Appoints Chief Medical Officer Annie C. Chen, M.D., MPH, to President of the Company’s Tyk2 Subsidiary      

  12/17/2019

  Nimbus Therapeutics announced the promotion of Chief Medical Officer, Annie C. Chen, M.D., MPH, to President of the company’s Tyk2 subsidiary, Nimbus Lakshmi, Inc.

• 

  BioSpace Movers & Shakers, Sept. 20

  9/20/2019

  Biotech and pharma companies from across the globe strengthen their leadership teams and boards of directors with this week's appointments.

• Nimbus Therapeutics Appoints Accomplished Biologist and Research Director Christine Loh, Ph.D., to Lead Biology Team

  9/19/2019

  Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, today announced that it has appointed Christine Loh, Ph.D., as Senior Vice President, Head of Biology.

• Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology

  7/9/2019

  Collaboration adds additional program focused on HPK1 inhibitors, potential medicines that could restore proper immune system activity in multiple tumor types

• Jnana Therapeutics Appoints Donald Nicholson, Ph.D., as Chair of its Board of Directors

  4/5/2019

  Jnana Therapeutics announced the appointment of Donald Nicholson, Ph.D., an accomplished scientist and executive, as chair of its Board of Directors.

• Nimbus Therapeutics Publishes First-Ever High-Resolution Structure of ATP-Citrate Lyase

  4/3/2019

  Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, today published research in Nature describing the first high-resolution structure of full-length human ATP-citrate lyase (ACLY), a building block of human metabolism

• 

  BioSpace Movers and Shakers: March 22

  3/22/2019

  Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.

• Nimbus Therapeutics Grows Scientific Team, Adding Leaders in Biology and Preclinical Development

  3/20/2019

  Announced the addition of two experts in drug discovery and development to its leadership team.

• 

  Companies Focus on STING Pathway to Boost Immune Response in Patients

  3/14/2019

  The drugs target a protein called STING (stimulator of interferon genes), which plays an important role in the innate immune system, which is the body’s first line of defense against various pathogens.